retatrutide nash trial Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide: Evidence, Safety & Options

"Our products are proven safe

Naturally occurring molecule rivals Ozempic in weight loss, sidesteps side effects Addiction experts need more tools, and this could be a powerful one In a world full of easy access to dopamine triggers, we're more vulnerable to addiction than ever, Lembke said

Another similar non-peptidic candidate, danuglipron (PF-06882961), was rationally designed to occupy the deep orthosteric core of the receptor, overlapping with the binding region of the N-terminal residues of GLP-1 that penetrate into the transmembrane cavity

[11] [12] These medications mimic naturally occurring hormones that regulate appetite, glucose metabolism, and energy balance